MALCOLM BRENNER to Neuroblastoma
This is a "connection" page, showing publications MALCOLM BRENNER has written about Neuroblastoma.
Connection Strength
3.180
-
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
Score: 0.396
-
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
Score: 0.267
-
Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009; 15(4):424-9.
Score: 0.221
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
Score: 0.218
-
Vaccine therapies for pediatric malignancies. Cancer J. 2005 Jul-Aug; 11(4):331-9.
Score: 0.173
-
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025 Apr; 31(4):1125-1129.
Score: 0.169
-
Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001 Oct 15; 94(2):228-36.
Score: 0.134
-
Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):692-5.
Score: 0.126
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.122
-
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
Score: 0.108
-
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
Score: 0.106
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.102
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.100
-
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
Score: 0.083
-
Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3.
Score: 0.081
-
Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
Score: 0.078
-
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
Score: 0.077
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.077
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.074
-
Retrovirus-mediated gene transfer as an approach to analyze neuroblastoma relapse after autologous bone marrow transplantation. Hum Gene Ther. 1992 Apr; 3(2):129-36.
Score: 0.069
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.062
-
A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008 Nov-Dec; 31(9):812-9.
Score: 0.055
-
Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007 Feb-Mar; 30(2):227-33.
Score: 0.048
-
A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
Score: 0.041
-
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
Score: 0.036
-
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res. 2002 Feb 15; 62(4):1123-8.
Score: 0.034
-
High-efficiency transduction of freshly isolated human tumor cells using adenoviral interleukin-2 vectors. Hum Gene Ther. 1996 Jun 20; 7(10):1233-9.
Score: 0.023
-
Use of gene marking in bone marrow transplantation. Cancer Detect Prev. 1996; 20(2):108-13.
Score: 0.022
-
Gene marking and autologous bone marrow transplantation. Ann N Y Acad Sci. 1994 May 31; 716:204-14; discussion 214-5, 225-7.
Score: 0.020
-
Gene transfer and bone marrow transplantation. Cold Spring Harb Symp Quant Biol. 1994; 59:691-7.
Score: 0.019
-
Gene marking to improve the outcome of autologous bone marrow transplantation. Prog Clin Biol Res. 1994; 389:587-91.
Score: 0.019
-
Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov; 10(5):457-62.
Score: 0.018